CLDX

NEUTRALProduct

Celldex Therapeutics, Inc.

2026-06-26

Price

$35.26

+3.43%

Score6.8Priority

Signals4/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume4.3xvs 20d avg

Analysis

CLDX is exhibiting high-conviction price discovery because institutional capital is rotating out of a cautious, tech-heavy macro regime and into idiosyncratic biotech catalysts. Recent positive long-term data for its lead drug barzolvolimab presented at the EAACI congress has fueled a technical breakout, supported by urgent institutional participation at 4.3x average volume. Because credit markets remain stable (OAS at 0.76%) despite the tech selloff, investors have the confidence to aggressively bid up CLDX, as evidenced by its +15.1% relative strength versus the SPY.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONBREAKOUT

Key Takeaways

Actionable Thesis: CLDX is in a confirmed breakout phase, absorbing capital rotating out of the tech sector due to strong clinical data and a clear timeline for Phase 3 results in Q4 2026.
Key Risk: The high realized volatility (42.6% annualized) and the biotech sector's inherent sensitivity to clinical updates mean any negative pipeline news could trigger a sharp technical breakdown.
What to Watch: Monitor the $28.56 line-in-the-sand level for critical technical support, alongside any interim pipeline updates or analyst rating changes following the recent EAACI data presentation.

← Back to 2026-06-26 View Full CLDX History →Yahoo Finance &nearr;